No other direct antagonistic targeting agent for CHI3L1 exists at this time, but future availability of such reagents will enable deeper investigation as to the role, function and therapeutic potential of targeting CHI3L1 in cardiovascular disease. The gene discussed is CHI3L1; the disease is cardiovascular disorder.